Silexion Prices $2.5M Offering at $0.65/Share with Warrants
SLXN is trading near its 52-week low of $0.43 (7.8% above the low).
Summary
Silexion Therapeutics priced a $2.5 million offering at $0.65 per share with warrants, a deep discount to its recent $1.87 price, to fund its SIL204 clinical trial and address a going concern warning.
Updates
· SEC 8-K — The offering closed on August 13, 2026, with net proceeds of approximately $2.1 million. The company converted $750,001 of the sponsor note into 1,153,848 shares at $0.65, reducing the note balance to $206,462. Prior to closing, 823,770 pre-funded warrants were exercised.
Key Events · Financing and Capital Events · SLXN
-
Offering Priced at Deep Discount
Silexion priced 2,028,619 ordinary shares at $0.65 per share with accompanying warrants, a 65% discount to the $1.87 closing price on August 7, 2026. The offering also includes 1,817,542 pre-funded warrants at $0.6499 each.
-
Gross Proceeds of $2.5M
The offering is expected to raise approximately $2.5 million in gross proceeds, with net proceeds of about $2.1 million after placement agent fees and expenses. The company will use the funds to advance its SIL204 clinical program and for general corporate purposes.
-
Massive Dilution Potential
The 2,028,619 shares offered represent a 150% increase over the 1,349,019 shares outstanding. If all pre-funded warrants and ordinary warrants are exercised, total shares outstanding could reach 5,932,934, a 340% increase. The company also plans to convert up to $750,001 of the A&R Sponsor Promissory Note into up to 1,153,848 additional shares at $0.65 per share.
-
Going Concern and Nasdaq Compliance
The company has a going concern warning, with cash of only $2.4 million as of March 31, 2026, and shareholders' equity below the $2.5 million Nasdaq minimum. The offering is intended to increase shareholders' equity and support continued listing compliance.
Analysis · SLXN · Life Sciences
Silexion Therapeutics has priced a best-efforts offering of 2,028,619 ordinary shares at $0.65 per share, each accompanied by an ordinary warrant, plus 1,817,542 pre-funded warrants at $0.6499 each. The offering is expected to close on August 13, 2026, and will raise approximately $2.1 million in net proceeds. The company intends to use the funds to advance its SIL204 clinical program and for general corporate purposes. The offering price of $0.65 is significantly below the last reported sale price of $1.87 on August 7, 2026, reflecting a deep discount that underscores the company's urgent need for capital. The company has a going concern warning, shareholders' equity below the Nasdaq minimum, and a pending delisting risk. This offering is a critical lifeline but comes with substantial dilution: the 2,028,619 shares alone represent a 150% increase over the 1,349,019 shares outstanding, and if all pre-funded warrants and ordinary warrants are exercised, total shares outstanding could reach 5,932,934, a 340% increase. The company also plans to convert up to $750,001 of the A&R Sponsor Promissory Note into up to 1,153,848 additional shares at the same $0.65 price, further diluting existing holders.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 962 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $492.8K. The 52-week trading range was $0.43 to $80.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.